Table 1. Patient's baseline characteristics

Characteristics of patients	No. Of patients N=26(%)
Age	
median,range	63(40~80)
Gender	
Men	10(38%)
Women	16(62%)
Primary lesion	
Left	15(58%)
Right	11(42%)
Metastatic site	
Lung	11(42%)
Liver	22(85%)
Lymph node	10(38%)
Others(bone,brain,peritoneum)	4(15%)
No. of treatment line	
Third line	19(73%)
Fourth line	4(15%)
Fifth line	3(12%)
KRAS status	
Mutation	15(58%)
Wild type	11(42%)
BRAF status	
Mutation	0(0%)
Wild type	26(100%)
PD-L1	
Positive	0(0%)
Negative	4(15%)
Unknown	22(85%)
MSI	
MSS	26(100%)
MSI-H	0(0%)
Her-2	
Positive	2(8%)
Negative	24(92%)
Previous anti-EGFR antibody	
Cetuximab	11(42%)
Previous antiangiogenic agent	
Bevacizumab	24(92%)
Regorafenib	5(18%)
PD-1 inhibitors	
Camrelizumab	1(4%)
Sintilimab	11(42%)

Tislelizumab	14(54%)

Table 2. Summary of treatment-related adverse events

irAE	Grade1-2(n)	Grade 3(n)	Grade 4(n)	Grade 5(n)	Total(%) N=26
hypothyroidism	2	0	0	0	2/26
rash	3	0	0	0	3/26
encephalitis	0	0	0	1	1/26
hepatitis	1	0	1	0	2/26
cardiotoxicity	0	0	0	1	1/26
fever	1	0	0	0	1/26
AE	Grade1-2(n)	Grade 3(n)	Grade 4(n)	Grade 5(n)	Total(%) N=26
diarrhea	1	0	0	0	1/26
proteinuria	2	1	0	0	3/26
Hypertension	3	1	0	0	4/26
Hand-foot syndrome	2	0	0	0	2/26
fatigue	3	0	0	0	3/26
vomiting	1	0	0	0	1/26

Table 3. efficacy data according to the biological characteristics

Characteristics of patients	ORR N/N (%)	DCR N/N (%)
Primary lesion		
Left	1/15(7%)	8/15(53%)
Right	0/11(0)	4/11(36%)
No. of treatment line		
Third line	1/19(5%)	11/19(57%)
Fourth line	0/4(0)	1/4(25%)
Fifth line	0/3(0)	0/3(0)
KRAS status		
Mutation	1/15(7%)	6/15(40%)
Wild type	0/11(0)	6/11(55%)
BRAF status		
Mutation	0(0%)	0(0%)

Wild type	1/26(4%)	12/26(46%)
PD-L1		
Positive	0(0%)	0(0)
Negative	0/4(0)	2/4(50%)
Unknown	1/22(5%)	10/22(45%)
MSI		
MSS	1/26(4%)	12/26(46%)
MSI-H	0(0)	0(0)
Her-2		
Positive	0/2(0)	1/2(50%)
Negative	1/24(4%)	11/24(46%)
Previous antiangiogenic agent		
Bevacizumab	1/24(4%)	11/24(46%)
Regorafenib	0/5(0)	1/5(20%)